A Newer Approach in the Treatment of Seborrheic Dermatitis With QR678 and QR678 Neo: A Prospective Pilot Study

The document presents a pilot study evaluating the effectiveness of QR678 Neo®, a patented formulation for hair regrowth, in treating seborrheic dermatitis. The study involved 40 patients aged 18 to 45 years, who showed significant improvements in symptoms after eight treatment sessions. The mean adherent scalp flaking score (ASFS) decreased from 60 to 12, and the Seborrheic Dermatitis Scalp Severity Index (SDSSI) score decreased from 11 to 2. These improvements were maintained at a 1-year follow-up. QR678 Neo® contains growth factors, vitamins, and minerals that reduce hair fall and inflammation. The treatment was easy to administer, relatively painless, and did not result in severe side effects or relapses at a 1-year follow-up. However, the study had limitations including a small sample size, lack of a control group, and a short follow-up period. Further research is recommended.